4
Changes in Ownership
Cartesian Therapeutics, Inc. Filed Acc 0001453687-24-000145
Chief Technology Officer sold 13,664 shares at an average $25.26 ($345,134)
- Chief Technology Officer acquired 13,664 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kurtoglu Metin Chief Technology Officer | 2024-12-09 | Option exercise | +10,763 | $1.41 | $15,176 | 61,796 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-12-09 | Sale | −6,224 | $25.26 | $157,236 | 55,572 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-12-09 | Sale | −4,539 | $25.83 | $117,257 | 51,033 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-12-10 | Option exercise | +2,901 | $1.41 | $4,090 | 53,934 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-12-10 | Sale | −2,901 | $24.35 | $70,640 | 51,033 | D |
| Derivatives | |||||||
| Kurtoglu Metin Chief Technology Officer | 2024-12-09 | Option exercise · Stock Option (Right to Buy) | −10,763 | 82,000 | D | ||
| Kurtoglu Metin Chief Technology Officer | 2024-12-10 | Option exercise · Stock Option (Right to Buy) | −2,901 | 79,099 | D | ||
| Open-market sales · 13,664 sh · avg $25.26 · $345,134 | |||||||
Loading xslF345X05/wk-form4_1733952508.xml…